Xeljanz xr and C-reactive protein increased - a phase IV clinical study of FDA data

Summary:

C-reactive protein increased is found among people who take Xeljanz xr, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Xeljanz xr and have C-reactive protein increased. It is created by eHealthMe based on reports of 82,316 people who have side effects when taking Xeljanz xr from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

82,316 people reported to have side effects when taking Xeljanz xr.
Among them, 190 people (0.23%) have C-reactive protein increased.


What is Xeljanz xr?

Xeljanz xr has active ingredients of tofacitinib citrate. eHealthMe is studying from 82,349 Xeljanz xr users for its effectiveness, alternative drugs and more.

What is C-reactive protein increased?

C-reactive protein increased is found to be associated with 2,137 drugs and 2,155 conditions by eHealthMe.

Number of Xeljanz xr and C-reactive protein increased reports submitted per year:

Could Xeljanz xr cause C-reactive protein increased?

Time on Xeljanz xr when people have C-reactive protein increased *:

Click here to view

Gender of people who have C-reactive protein increased when taking Xeljanz xr*:

Click here to view

Age of people who have C-reactive protein increased when taking Xeljanz xr *:

Click here to view

Common drugs people take besides Xeljanz xr *:

Click here to view

Common side effects people have besides C-reactive protein increased *:

Click here to view

Common conditions people have *:

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Xeljanz xr and have C-reactive protein increased?

Check whether C-reactive protein increased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was C-reactive protein increased and when was it recovered:

Expand to all the drugs that have ingredients of tofacitinib citrate:

Alternative drugs to, pros and cons of Xeljanz xr:

Common Xeljanz xr side effects:

Browse all side effects of Xeljanz xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

C-reactive protein increased treatments and more:

COVID vaccines that are related to C-reactive protein increased:

Common drugs associated with C-reactive protein increased:

All the drugs that are associated with C-reactive protein increased:

Common conditions associated with C-reactive protein increased:

All the conditions that are associated with C-reactive protein increased:

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz xr) and Xeljanz xr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: